Caspofungin therapy for Aspergillus lung infection in a boy with chronic granulomatous disease
- 1 February 2003
- journal article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 22 (2) , 199-200
- https://doi.org/10.1097/01.inf.0000050460.55352.dd
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium sppAntimicrobial Agents and Chemotherapy, 2002
- Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan AntigenemiaAntimicrobial Agents and Chemotherapy, 2002
- A Randomized Double‐Blind Study of Caspofungin versus Amphotericin for the Treatment of Candidal EsophagitisClinical Infectious Diseases, 2001
- Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infectionsExpert Opinion on Investigational Drugs, 2001
- Caspofungin acetate: An antifungal agentAmerican Journal of Health-System Pharmacy, 2001
- CaspofunginDrugs, 2001
- Chronic Granulomatous Disease: Report on a National Registry of 368 PatientsMedicine, 2000
- Virulence of catalase-deficient aspergillus nidulans in p47(phox)-/- mice. Implications for fungal pathogenicity and host defense in chronic granulomatous disease.Journal of Clinical Investigation, 1998
- Chronic Granulomatous Disease: The Solving of a Clinical Riddle at the Molecular LevelClinical Immunology and Immunopathology, 1993
- Biological Defense Mechanisms. THE PRODUCTION BY LEUKOCYTES OF SUPEROXIDE, A POTENTIAL BACTERICIDAL AGENTJournal of Clinical Investigation, 1973